CoChat

Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults

The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.

Abstract

Escitalopram (escitalopram oxalate; Cipralex, Lexapro), a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD), demonstrates a highly selective and potent, dose-dependent inhibition of the human serotonin transporter, inhibiting serotonin reuptake into presynaptic nerve terminals and thus increasing serotonergic activity in the CNS. With regard to primary endpoints (such as improved scores on the Montgomery-Asberg Depression Rating Scale [MADRS] and the Hamilton Depression Rating Scale [HAM-D]), escitalopram was generally more effective than placebo, at least as effective as citalopram, and generally at least as effective as other comparator drugs, including the SSRIs fluoxetine, paroxetine and sertraline, the serotonin-noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) venlafaxine extended release and duloxetine, and the aminoketone bupropion in adult patients with MDD in short-term, well designed trials. Moreover, it demonstrated a rapid onset of antidepressant action. Escitalopram was also found to be cost effective in several studies, dominating other SSRIs and venlafaxine extended release. Maintenance therapy is commonly required to prevent recurrence of depression. Long-term trials corroborated short-term results, with escitalopram demonstrating greater efficacy than placebo in relapse prevention. Additionally, escitalopram was at least as effective as citalopram, paroxetine and duloxetine in long-term comp…

Overview

Integrity signals

Registry

Crossref · 10.2165/11204760-000000000-00000

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 99 references

Research works printed but not linked: 10

  1. Greden, 2001, J Clin Psychiatry, 62, 5
  2. Lecrubier, 2001, J Clin Psychiatry, 62, 4
  3. Lepola, 2003 Jul, Int Clin Psychopharmacol, 18, 211, 10.1097/00004850-200307000-00003 · DOI · Paper page
  4. Lalit, 2004, Ind J Psychiatry, 46, 333
  5. Asnis, 2008 Jul, Int J Neuropsychopharmacol, 11, 189
  6. Kasper, 2005 Oct, Am J Ger Psychiatr, 13, 884, 10.1097/00019442-200510000-00008 · DOI
  7. Kongsakon, 2008 Jul, J Med Assoc Thai, 91, 1117
  8. Bramness, 2005 Sep 22, Tidsskr Nor Laegeforen, 125, 2470
  9. Thase, 2008, Psychopharmacol Bull, 41, 58
  10. Cipriani, 2009, Cochrane Database Syst Rev, &NA;, CD006532

Cited by

See all 66

Metadata

Authors
Garnock-Jones, K. P., & McCormack, P. L.
Affiliations
Wolters Kluwer Health (NZ)
Corresponding author
Garnock-Jones, Karly P.
Venue
CNS Drugs
Published
2010-09
Volume
24
Issue
9
Pages
769-796
ISSN
1172-7047 (ISSN-L)
OpenAlex
W2042587943
Cited by
66
References
99
Citations by year
2026: 2 · 2025: 3 · 2024: 2 · 2023: 8 · 2022: 6 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 6 · 2014: 2 · 2013: 4 · 2012: 3
FWCI
0.43
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords
escitalopram, selective serotonin reuptake inhibitors, major depressive disorder, serotonin transporter inhibition, antidepressant efficacy, sexual dysfunction, drug interactions, relapse prevention, maintenance therapy, cost-effectiveness, adverse events, duloxetine, paroxetine, venlafaxine
MeSH terms
Adult, Major Depressive Disorder, Depressive Disorder, Major, Humans, Citalopram, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults. https://app.cochat.ai/papers/10.2165/11204760-000000000-00000
The paper
Garnock-Jones, K. P., & McCormack, P. L. (2010). Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults. CNS Drugs. https://doi.org/10.2165/11204760-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.